MARKET

AIM

AIM

Aim Immunotech
AMEX
0.4413
-0.0087
-1.93%
Opening 14:38 11/28 EST
OPEN
0.4498
PREV CLOSE
0.4500
HIGH
0.4568
LOW
0.4401
VOLUME
40.09K
TURNOVER
10.22K
52 WEEK HIGH
1.510
52 WEEK LOW
0.4200
MARKET CAP
21.22M
P/E (TTM)
-1.0133
1D
5D
1M
3M
1Y
5Y
AIM ImmunoTech GAAP EPS of -$0.13 misses by $0.01
Seekingalpha · 11/15 12:39
BRIEF-Aim Immunotech Reports Third Quarter 2022 Financial Results
Reuters · 11/15 12:12
AIM ImmunoTech Q3 EPS $(0.13) Down From $(0.08) YoY
Benzinga · 11/15 12:07
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) a...
GlobeNewswire · 11/14 12:00
BRIEF-AIM ImmunoTech Announces Corporate Governance Enhancements
Reuters · 11/09 14:42
AIM ImmunoTech Announces Corporate Governance Enhancements
OCALA, Fla., November 09, 2022--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the following corporate governance enhancements:
Business Wire · 11/09 14:00
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
OCALA, Fla., November 03, 2022--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that shareholders have re-elected all three of the Company’s directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at th...
Business Wire · 11/03 16:34
AIM ImmunoTech soars on FDA orphan drug tag for Ampligen to treat Ebola virus disease
Seekingalpha · 11/02 12:51
More
About AIM
AIM ImmunoTech Inc. is an immuno-pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Webull offers kinds of AIM ImmunoTech Inc stock information, including AMEX:AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.